In about 16 hours, the Sept trading month will begin In about 16 hours the Sept trading month will begins.
We have been told , Sept will be/ is supposed to be the forwarded news on the PanCan trial.
For those new, or just coming back....the Pan Can trial is a phase 3 trial, for pancreatic cancer.
Featuring the extraordinary good results of a phase 2 trial with Roche & oncs pelareorep.
The results were good enough to grant fast track approval & the acceptance of PanCan.
it needs to be understood the acceptance of PanCan is huge!
They have in- place not only the physical infrastructure, meaning Multiple trial locations & patients lined up.
They also have the very important administrative & contact infrastructure with the FDA.
Pancan's only reason of existence is moving the standard of care for pancreatic cancer forward.
Beyond the PanCan, realm comes the bigger picture of a phase 3 trial for onc.
Yes, long awaited!
They do need & have stated as such, a pharma partner to proceed.
Back to my opening statement. Roche, Pfizer & Incyte have the closest ties to Onc & Pela.
Being involved with multiple co- therapy trials, they have the inside track on trial data.
Roche?
Would seem to be top contender.
They do also have a larger focus with the Goblet trial.
The results & expected second half if this year. Meaning between now & Dec.
They mentioned " exciting presentations" as the ASCO symposium.
The deadline for standard abstracts is Sept 19th.
Negotiations?
that being for a phase 3 partner. Roche could & most likely be waiting to see solid enough results.
ironically the longer the wait, assuming survivals are continuing, the more valuable Onc becomes.
So, it is possible the " final announcement " may be delayed, pending Goblet results.
Total takeover?
Could be announced, tomorrow, next month, next year or never.
From ONC's perspective:They are as close as ever in history to a phase 3 & market acceptance, for pancreatic cancer. Plus phase 3 ready MBc + on- going CAR-T trials. + a few other outlooks.
Assuming any one of those gets to approval, Onc becones a multi billion $$ company.
" don't want to undersell the company"
From an aquiring pharma;
Pelareorep needs solid enough proof that any investment can be worth the risk.
proof comes from studies.
Yes , they could buy early , at a discount. They carry the risk.
So until the doubts are proved out, Onc could be bought out however not at top price.
My likely scinario. A phase 3 partnership, followed by a complete buyout, once phase 3 starts to prove itself.
regards